Role of the funding source
The study was designed and performed by the study team of the UMC Utrecht at the Dermatology and Allergology clinic, and partly financed by Pharming Technologies, which was informed about the study protocol and was notified regarding inclusion of patients and progress in order to organize drug delivery. The company also donated rhC1-INH for patient 1 for six months treatment after the last study visit.